期刊
BLOOD
卷 123, 期 18, 页码 2791-2796出版社
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2014-01-550905
关键词
-
类别
资金
- Peter and Helen Bing Foundation
- International Waldenstrom's Macroglobulinemia Foundation
- Coyote Fund for WM
- D'Amato Family Fund for Genomic Discovery
- Edward and Linda Nelson Fund for WM Research
Whole genome sequencing has revealed activating somatic mutations in MYD88 (L265P) and CXCR4 in Waldenstrom macroglobulinemia (WM). CXCR4 somatic mutations in WM are the first ever reported in human cancer and are similar to nonsense (NS) and frameshift (FS) germline mutations found in warts, hypogammaglobulinemia, infections and myelokathexis (WHIM) syndrome. We genotyped lymphoplasmacytic cells from 175 WM patients and observed significantly higher bone marrow (BM) disease involvement, serum immunoglobulin-M levels, and symptomatic disease requiring therapy, including hyperviscosity syndrome in those patients with MYD88(L265P) CXCR4(WHIM/NS) mutations (P < .03). Patients with MYD88(L265P) CXCR4(WHIM/FS) or MYD88(L265P) CXCR4 WILDTYPE (WT) had intermediate BM and serum immunoglobulin-M levels; those with MYD88(WT) CXCR4(WT) showed lowest BM disease burden. Fewer patients with MYD88(L265P) and CXCR4(WHIM/FS or NS) vs MYD88(L265P) CXCR4(WT) presented with adenopathy (P < .01), further delineating differences in disease tropism based on CXCR4 status. Neither MYD88 nor CXCR4 mutations correlated with SDF-1a (RS1801157) polymorphisms in 54 patients who were genotyped for these variants. Unexpectedly, risk of death was not impacted by CXCR4 mutation status, but by MYD88(WT) status (hazard ratio 10.54; 95% confidence interval 2.4-46.2, P = .0018). Somatic mutations in MYD88 and CXCR4 are important determinants of clinical presentation and impact overall survival in WM. Targeted therapies directed against MYD88 and/or CXCR4 signaling may provide a personalized treatment approach to WM.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据